Rockefeller Capital Management
RPRX icon

Rockefeller Capital Management’s Royalty Pharma RPRX Stock Holding History

Rockefeller Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.05M Sell
90,020
-939
-1% -$48.9K 0.01% 970
2026
Q1 		$4.36M Buy
90,959
+3,145
+4% +$138K 0.01% 971
2025
Q4 		$3.39M Buy
87,814
+81,747
+1,347% +$3.12M 0.01% 1018
2025
Q3 		$214K Buy
+6,067
New +$220K ﹤0.01% 2200
2024
Q3 		– Sell
-15,873
Closed -$419K – 1677
2024
Q2 		$419K Sell
15,873
-4,129
-21% -$114K ﹤0.01% 1486
2024
Q1 		$607K Sell
20,002
-672,962
-97% -$19.8M ﹤0.01% 1412
2023
Q4 		$19.5M Buy
692,964
+663,963
+2,289% +$18.2M 0.07% 295
2023
Q3 		$787K Buy
29,001
+3,940
+16% +$117K ﹤0.01% 1167
2023
Q2 		$770K Buy
25,061
+171
+0.7% +$5.79K ﹤0.01% 1181
2023
Q1 		$896K Sell
24,890
-69,113
-74% -$2.56M ﹤0.01% 1120
2022
Q4 		$3.71M Sell
94,003
-9,257
-9% -$386K 0.02% 585
2022
Q3 		$4.15M Buy
103,260
+3,373
+3% +$144K 0.02% 579
2022
Q2 		$4.2M Sell
99,887
-219
-0.2% -$8.98K 0.02% 565
2022
Q1 		$3.9M Sell
100,106
-26,517
-21% -$1.04M 0.02% 601
2021
Q4 		$5.04M Buy
126,623
+44,797
+55% +$1.74M 0.02% 536
2021
Q3 		$2.96M Buy
81,826
+66,250
+425% +$2.57M 0.02% 635
2021
Q2 		$638K Buy
15,576
+3,072
+25% +$131K ﹤0.01% 1094
2021
Q1 		$545K Sell
12,504
-1,359
-10% -$64.4K ﹤0.01% 990
2020
Q4 		$693K Buy
13,863
+9,339
+206% +$396K 0.01% 806
2020
Q3 		$190K Buy
4,524
+2,524
+126% +$108K ﹤0.01% 1054
2020
Q2 		$97K Buy
+2,000
New +$99K ﹤0.01% 1179

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rockefeller Capital Management's RPRX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Royalty Pharma (RPRX) stake by 1% in Q2 2026, selling an estimated $48.9K and leaving 90,020 shares worth $5.05M. The position accounts for 0.01% of the portfolio, ranked #970.

Rockefeller Capital Management first reported a position in RPRX in Q2 2020 and has held it in 21 quarters since. The position peaked at $19.5M in Q4 2023. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Rockefeller Capital Management held 90,020 shares of Royalty Pharma worth $5.05M as of Q2 2026.
  • Rockefeller Capital Management sold 939 Royalty Pharma shares in Q2 2026, an estimated $48.9K.
  • Royalty Pharma made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #970 holding.
  • Rockefeller Capital Management first reported a position in Royalty Pharma in Q2 2020 and has held it in 21 quarters since.
  • Rockefeller Capital Management's Royalty Pharma position peaked at $19.5M in Q4 2023.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.